PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsLutropin alfa
Lutropin alfa
Luveris, Pergoveris (lutropin alfa) is a protein pharmaceutical. Lutropin alfa was first approved as Luveris on 2000-11-29. It is used to treat female infertility in the USA. It has been approved in Europe to treat female infertility and ovulation induction. The pharmaceutical is active against lutropin-choriogonadotropic hormone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
therapeuticsD013812
investigative techniquesD008919
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
female infertilityEFO_0008560D007247N97
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03G: Gonadotropins and other ovulation stimulants
— G03GA: Gonadotropins
— G03GA07: Lutropin alfa
HCPCS
No data
Clinical
Clinical Trials
279 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471—C614252431065
InfertilityD007246HP_0000789—597132254
Breast neoplasmsD001943EFO_0003869C5031051321
Female infertilityD007247EFO_0008560N972115413
HypogonadismD007006HP_0000044E23.0121228
Ovulation inductionD010062———421—7
Fertilization in vitroD005307—————415
ObesityD009765EFO_0001073E66.9———112
PregnancyD011247EFO_0002950Z33.1———112
HyperprolactinemiaD006966HP_0000870E22.1———112
Show 9 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AdenocarcinomaD000230———54——9
Triple negative breast neoplasmsD064726———23——5
Assisted reproductive techniquesD027724————2—13
Castration-resistant prostatic neoplasmsD064129——221——3
Precocious pubertyD011629—E22.8—12——3
NeoplasmsD009369—C80—11——2
Bone neoplasmsD001859EFO_0003820D16——1——1
FertilityD005298————1——1
PainD010146EFO_0003843R52——1——1
Fertility preservationD059247————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ContraceptionD003267——11——13
Primary ovarian insufficiencyD016649EFO_0004266E28.311——12
Growth disordersD006130———1——12
Male breast neoplasmsD018567———1———1
MenorrhagiaD008595EFO_0003945N92.0—1———1
Premature menopauseD008594HP_0008209E28.3111———1
MenopauseD008593EFO_0003922N9511———1
Hot flashesD019584——11———1
Urologic neoplasmsD014571—C64-C6811———1
DwarfismD004392HP_0003510E34.31—1———1
Show 4 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Polycystic ovary syndromeD011085EFO_0000660E28.25———38
HyperandrogenismD017588——4———15
Healthy volunteers/patients———3———14
PubertyD011627EFO_0001382—3————3
EndometriosisD004715EFO_0001065N801———12
Hemophilia aD006467EFO_0007267D661————1
GynatresiaD006175EFO_1001335N85.61————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Male infertilityD007248EFO_0004248N46————22
Autonomic nervous system diseasesD001342EFO_0009532G90————22
Menstrual cycleD008597——————22
Covid-19D000086382—U07.1————22
Preimplantation diagnosisD019836——————11
Spinal cord injuriesD013119EFO_1001919—————11
Systemic sclerodermaD012595EFO_0000717M34————11
Uterine inertiaD014593EFO_1001863O62.2————11
Hematologic diseasesD006402EFO_0005803D75.9————11
ThalassemiaD013789EFO_1001996D56————11
Show 22 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLutropin alfa
INNlutropin alfa
Description
Lutropin beta chain precursor (Luteinizing hormone beta subunit) (LSH-beta)
Classification
Protein
Drug classtricyclic compounds; atropine derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201419
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID3JGY52XJNA (ChemIDplus, GSRS)
Target
Agency Approved
LHCGR
LHCGR
Organism
Homo sapiens
Gene name
LHCGR
Gene synonyms
LCGR, LGR2, LHRHR
NCBI Gene ID
Protein name
lutropin-choriogonadotropic hormone receptor
Protein synonyms
hypergonadotropic hypogonadism, LHR, LSH-R, Luteinizing hormone receptor, lutropin/choriogonadotropin receptor
Uniprot ID
Mouse ortholog
Lhcgr (16867)
lutropin-choriogonadotropic hormone receptor (P30730)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Lutropin alfa
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 5,125 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
323 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use